UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 

As part of Psoriasis Action Month, Camille Lee, Head of U.S. Immunology at UCB, shares how UCB is helping find and bridge gaps in psoriatic disease care. 

Today, UCB issued the following statement from Jeffrey Stark, M.D., Head of U.S. Medical Immunology, on the recent update by the ICD-10 Coordination and Maintenance Committee to endorse the creation of a new sub-category (M45.A) for non-radiographic axial spondyloarthritis (nr-axSpA). 

Congratulations to Anita Moser, Head of U.S. Neurology Assets and Optimization, and Erica Puntel, U.S. Neurology and Global Digital Business Transformation Communications Lead, for their recognition as Healthcare Businesswomen's Association (HBA) Rising Stars for 2021.